Howie just said "50% of dermatologists would try their patients on Sofdra..."
The figures we have been looking at was in the 1% range which would be close to a $B per annum turnover and a shareprice in the low +$dollar region. This means my figures have been wrong, BOT's potential need to have a zero on the end of the shareprice, holy crap!!
Ann: Botanix Commercial Day Webinar Presentation, page-37
-
- There are more pages in this discussion • 160 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $671.1M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 37.0¢ | $1.949M | 5.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 163455 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 33207 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |